EricaLeighCampagnaroMD

Oncology • Ann Arbor, MI

Assistant Professor, Medicine, Case Western Reserve University School of Medicine

Join to view full profile

Dr. Campagnaro is on Doximity

As a Doximity member you'll join over two million verified healthcare professionals in a private, secure network.

Connect with other colleagues in the same hospital or clinic
Search all U.S. specialist profiles and refer a patient
Read the latest clinical news and earn CME/CEU credits

See Dr. Campagnaro's full profile

Already have an account?

Office
1500 E Medical Centre Drive
Ann Arbor, MI 48109
Phone+1 734-647-8901
Is this information wrong?

Education & Training

University of Texas Health Science Center at HoustonFellowship, Hematology and Medical Oncology, 2004 - 2007
University of Texas Medical Branch HospitalsResidency, Internal Medicine, 2000 - 2003
Louisiana State University School of Medicine in New OrleansClass of 2000

Certifications & Licensure

MI State Medical License 2007 - 2026
OH State Medical License 2009 - 2019
TX State Medical License 2004 - 2010
American Board of Internal Medicine Internal Medicine
American Board of Internal Medicine Hematology

Clinical Trials

Low-Dose Azacitidine, Lenalidomide, and Low-Dose Dexamethasone in Relapsed or Refractory Multiple Myeloma Start of enrollment: 2010 Jun 01
Completed
Phase 1, Phase 2
Lenalidomide or Observation in Treating Patients With Asymptomatic High-Risk Smoldering Multiple Myeloma Start of enrollment: 2011 Jan 24
Active, not recruiting
Phase 3
Bendamustine in Combination With Bortezomib and Pegylated Liposomal Doxorubicin for Multiple Myeloma Start of enrollment: 2010 Jul 01
Terminated
Phase 1, Phase 2
Fludarabine, Velcade and Rituximab for Relapsed or Refractory Follicular Non-Hodgkin Lymphoma Start of enrollment: 2010 Oct 01
Terminated
Phase 2
MLN9708 (Ixazomib) in Combination With Panobinostat and Dexamethasone in Multiple Myeloma Start of enrollment: 2014 May 22
Completed
Phase 1, Phase 2
Bortezomib, Dexamethasone, and Cyclophosphamide in Treating Older Patients With Multiple Myeloma Start of enrollment: 2015 Apr 01
Withdrawn
Phase 2
Join now to see all

Publications & Presentations

PubMed

Administration of teclistamab in four patients with multiple myeloma requiring hemodialysis.
Christy J Khouderchah, Madeleine Ochs, Zahra Mahmoudjafari, Jordan Snyder, Iman Ahmed, Victoria R Nachar, Matthew Pianko, Erica Campagnaro> ;Journal of Oncology Pharmacy Practice. 2024 Apr 5
Waldenström Macroglobulinemia/Lymphoplasmacytic Lymphoma, Version 2.2024, NCCN Clinical Practice Guidelines in Oncology.
Kumar, S., Callander, N., Adekola, K., Anderson, L., Baljevic, M., Baz, R., Campagnaro, E., Castillo, J., Costello, C., D'Angelo, C., Derman, B., Devarakonda, S., Else...> ;Journal of the National Comprehensive Cancer Network. 2024 Jan 1
1 citations
Multiple Myeloma, Version 2.2024, NCCN Clinical Practice Guidelines in Oncology.
Shaji K Kumar, Natalie S Callander, Kehinde Adekola, Larry D Anderson Jr, Muhamed Baljevic, Rachid Baz, Erica Campagnaro, Jorge J Castillo, Caitlin Costello, Christoph...> ;Journal of the National Comprehensive Cancer Network. 2023 Dec 1
Lenalidomide in the treatment of anti-myelin-associated glycoprotein neuropathy: A phase 1 study to identify the maximum tolerated dose.
Amro M Stino, Naresh Bumma, Rachel Smith, Long Davalos, Jeff Allen, Jing Christine Ye, Matthew Pianko, Erica Campagnaro, Cassandra Fierro, Abdelrahman Awad, Ben Murdoc...> ;European Journal of Neurology. 2024 Mar 1
5 citations
Systemic Light Chain Amyloidosis, Version 2.2023, NCCN Clinical Practice Guidelines in Oncology.
Shaji K Kumar, Natalie S Callander, Kehinde Adekola, Larry D Anderson Jr, Muhamed Baljevic, Erica Campagnaro, Jorge J Castillo, Caitlin Costello, Christopher D'Angelo,...> ;Journal of the National Comprehensive Cancer Network. 2023 Jan 1
2 citations
Daratumumab Interferes with Allogeneic Crossmatch Impacting Immunological Assessment in Solid Organ Transplantation.
Chak-Sum Ho, Kyle R Putnam, Christine R Peiter, Walter F Herczyk, John A Gerlach, Yee Lu, Erica L Campagnaro, Kenneth J Woodside, Matthew F Cusick> ;Journal of Clinical Medicine. 2022 Oct 14
13 citations
Cell-free DNA for the detection of emerging treatment failure in relapsed/ refractory multiple myeloma.
Johannes M Waldschmidt, Andrew J Yee, Tushara Vijaykumar, Ricardo A Pinto, Julia Frede, Praveen Anand, Giada Bianchi, Guangwu Guo, Sayalee Potdar, Charles Seifer, Moni...> ;Leukemia. 2022 Apr 1
70 citations
NCCN Guidelines® Insights: Multiple Myeloma, Version 3.2022.
Natalie S Callander, Muhamed Baljevic, Kehinde Adekola, Larry D Anderson, Erica Campagnaro, Jorge J Castillo, Caitlin Costello, Srinivas Devarakonda, Noura Elsedawy, M...> ;Journal of the National Comprehensive Cancer Network. 2022 Jan 1
1 citations
Laryngotracheobronchial Amyloidosis: Patterns of Presentation and Management.
Sarah M. Dermody, Erica L. Campagnaro, Robbi A. Kupfer, Norman D. Hogikyan, Robert J. Morrison> ;The Annals of Otology, Rhinology, and Laryngology. 2021 Aug 28
2 citations
Multiple myeloma presenting as cryoglobulinemic vasculitis.
John S. Runge, Tracie L. Pearson, David F. Keren, Scott D. Gitlin, Erica L. Campagnaro, Lori Lowe, Johann E. Gudjonsson, Alexandra C. Hristov> ;JAAD Case Reports. 2021 Mar 29
6 citations
DNA methylation inhibition in myeloma: Experience from a phase 1b study of low-dose continuous azacitidine in combination with lenalidomide and low-dose dexamethasone ...
Jack Khouri, Beth Faiman, Dale Grabowski, Reda Z. Mahfouz, Shahper N. Khan, Wei Wei, Jason Valent, Robert M. Dean, Christy J. Samaras, Babal K. Jha, Hillard M. Lazarus...> ;Seminars in Hematology. 2021 Jan 1
151 citations
Multiple myeloma, version 3.2021
Shaji Kumar, Natalie S. Callander, Kehinde Adekola, Larry D. Anderson, Muhamed Baljevic, Erica L. Campagnaro, Jorge J. Castillo, Jason C. Chandler, Caitlin Costello, Y...> ;Journal of the National Comprehensive Cancer Network. 2020 Dec 2
13 citations
Optimal sequence of daratumumab and elotuzumab in relapsed and refractory multiple myeloma.
Emily K Hoylman, Anna Brown, Anthony J. Perissinotti, Bernard L. Marini, Matthew J. Pianko, Jing Christine Ye, Erica L. Campagnaro, Victoria R Nachar> ;Leukemia & Lymphoma. 2020 Feb 23
174 citations
Ruxolitinib in adult patients with secondary haemophagocytic lymphohistiocytosis: an open-label, single-centre, pilot trial.
Asra Ahmed, Samuel A. Merrill, Fares Alsawah, Paula L. Bockenstedt, Erica L. Campagnaro, Sumana Devata, Scott D. Gitlin, Mark S. Kaminski, Alice M. Cusick, Tycel Phill...> ;The Lancet. Haematology. 2019 Sep 16
10 citations
Use of Bone-Modifying Agents in Myeloma and Bone Metastases: How Recent Dosing Interval Studies Have Affected Our Practice
Erica L. Campagnaro, Melissa A. Reimers, Angel Qin, Ajjai Alva, Bryan J. Schneider, Catherine Van Poznak> ;Journal of Oncology Practice. 2018 Aug 10
9 citations
A family-centered intervention for the transition to living with multiple myeloma as a chronic illness: A pilot study
Susan R. Mazanec, Sarah J Miano, Linda Baer, Erica L. Campagnaro, Abdus Sattar, Barbara J. Daly> ;Applied Nursing Research. 2017 Jun 1
5 citations
Retrospective study of the incidence and patterns of arterial and venous thrombosis in Chinese versus African American patients with multiple myeloma.
Radha Raghupathy, Sabarish Ayyappan, Dhivya Prabhakar, Erica L. Campagnaro, Frankie Mo, Wa Li, Edwin P. Hui, Anthony T.C. Chan, Kenny I.K. Lei> ;British Journal of Haematology. 2017 Jan 1
16 citations
Management of multiple myeloma in older adults: Gaining ground with geriatric assessment.
Tanya M. Wildes, Erica L. Campagnaro> ;Journal of Geriatric Oncology. 2017 Jan 1
5 citations
Comparison of 2 Carmustine-Containing Regimens in the Rituximab Era: Excellent Outcomes Even in Poor-Risk Patients
Paolo Caimi, Basem M. William, Carlos H. Silva Rondon, Pingfu Fu, Brenda W. Cooper, Erica L. Campagnaro, Stanton L. Gerson, Jane Reese-Koc, R. M. Fox, Richard J. Crege...> ;Biology of Blood and Marrow Transplantation. 2015 Nov 1
9 citations
Neoplastic and non‐neoplastic complications of solid organ transplantation in patients with preexisting monoclonal gammopathy of undetermined significance
Teresa E. Goebel, Nicholas K. Schiltz, Kenneth J. Woodside, Aiswarya Chandran Pillai, Paolo Caimi, Hillard M. Lazarus, Siran M. Koroukian, Erica L. Campagnaro> ;Clinical Transplantation. 2015 Sep 1
1 citations
Management of Elderly Patients with Plasma Cell Myeloma.
Erica L. Campagnaro, Teresa E. Goebel, Hillard M. Lazarus> ;Drugs & Aging. 2015 May 30
4 citations
Hypertensive emergency, matlike telangiectasias, and calciphylaxis in POEMS syndrome.
Roberto A. Novoa, Kord Honda, Erica L. Campagnaro, Meg R. Gerstenblith> ;JAMA Dermatology. 2014 Jun 1
14 citations
Secondary MGUS after autologous hematopoietic progenitor cell transplantation in plasma cell myeloma: a matter of undetermined significance
G V Manson, Erica L. Campagnaro, A Balog, David L. Kaplan, Scott R. Sommers, Pingfu Fu, S V Rajkumar, Hillard M. Lazarus> ;Bone Marrow Transplantation. 2012 Sep 1
70 citations
Lenalidomide, bortezomib, pegylated liposomal doxorubicin, and dexamethasone in newly diagnosed multiple myeloma: a phase 1/2 Multiple Myeloma Research Consortium trial
Andrzej Jakubowiak, Kent A. Griffith, Donna E. Reece, Craig C. Hofmeister, S. Lonial, Todd M. Zimmerman, Erica L. Campagnaro, Robert L. Schlossman, Jacob P. Laubach, N...> ;Blood. 2011 Jul 21
Survival outcomes in elderly patients with plasma cell myeloma: The three-decade Eastern Cooperative Oncology Group (ECOG) experience.
Campagnaro EL, Jacobus SJ, Uno H, Oken MM, Kyle RA, Rajkumar SV, Greipp PR, Vesole DH, Weiss M, Fonseca R, Lazarus HM> ;J. Clin. Oncol.. 2011-05-20
Join now to see all

Abstracts/Posters

Circulating Tumor DNA in the Peripheral Blood As Early Predictor of Clinical Outcome in Relapsed/ Refractory Multiple Myeloma
Erica L. Campagnaro, 61st Annual American Society of Hematology Meeting, Orlando, FL, 12/9/2019
Translational and Clinical Evidence of a Differentiated Profile for the Novel CELMoD, Iberdomide (CC-220)
Erica L. Campagnaro, 61st Annual American Society of Hematology Meeting, Orlando, FL, 12/8/2019
A Phase II Study of Elotuzumab in Combination with Pomalidomide, Bortezomib, and Dexamethasone in Relapsed and Refractory Multiple Myeloma
Erica L. Campagnaro, 61st Annual American Society of Hematology Meeting, Orlando, FL, 12/8/2019
Aneuploidy Is Associated with Inferior Survival in Relapsed Refractory Multiple Myeloma Patients
Erica L. Campagnaro, 61st Annual American Society of Hematology Meeting, Orlando, FL, 12/9/2019
Defining the Differentiation States of Multiple Myeloma at Single Cell Resolution Reveals Opportunities for Immunotherapy
Erica L. Campagnaro, 61st Annual American Society of Hematology Meeting, Orlando, FL, 12/8/2019
A Phase 2 Study with Minimal Residual Disease (MRD) Driven Adaptive Strategy in Treatment for Newly Diagnosed Multiple Myeloma with Upfront Daratumumab-Based Therapy
Erica L. Campagnaro, 61st Annual American Society of Hematology Meeting, Orlando, FL, 12/8/2019
Join now to see all

Lectures

Ruxolitinib Is Active and Well Tolerated in Adult Patients with Secondary Hemophagocytic Lymphohistiocytosis: Preliminary Results of an Ongoing, Open-Label, Single Cen...
2018 ASH Annual Meeting - San Diego, CA - 12/1/2018